A Study of Sacituzumab Govitecan in People With Mesothelioma
Status:
RECRUITING
Trial end date:
2029-06-21
Target enrollment:
Participant gender:
Summary
Participants will receive sacituzumab govitecan until their disease gets worse (progresses), they have severe side effects and cannot continue study treatment, or the participants or the study doctor thinks it's in your best interest to stop treatment.